Invention Grant
![Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid](/docs/US/2018-03-06/US09908850B2/abs.jpg.600x600.jpg)
- Patent Title: Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid
-
Application No.: US15468419Application Date: 2017-03-24
-
Publication No.: US09908850B2Publication Date: 2018-03-06
- Inventor: Joseph Francis Krzyzaniak , Jason Albert Leonard
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent Stephanie J. Monaco
- Main IPC: C07D207/34
- IPC: C07D207/34 ; C07C211/07 ; C07C229/26 ; C07D295/027
![Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid](/abs-image/US/2018/03/06/US09908850B2/abs.jpg.150x150.jpg)
Abstract:
Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
Public/Granted literature
Information query
